Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer?: Lessons from COMET-2

Peter B Østergren; Teemu J Murtola; Mikkel Fode

doi:10.1016/j.eururo.2018.12.016

Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2

Peter B Østergren, Teemu J Murtola, Mikkel Fode

Afdeling for Urinvejssygdomme HGH

Originalsprog	Engelsk
Tidsskrift	European Urology
ISSN	0302-2838
DOI	https://doi.org/10.1016/j.eururo.2018.12.016
Status	Udgivet - 17 dec. 2018

Adgang til dokumentet

10.1016/j.eururo.2018.12.016

Citationsformater

@article{9b0d29010c3042e09105e776fb6242f3,

title = "Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer?: Lessons from COMET-2",

author = "{\O}stergren, {Peter B} and Murtola, {Teemu J} and Mikkel Fode",

year = "2018",

month = dec,

day = "17",

doi = "10.1016/j.eururo.2018.12.016",

language = "English",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer?

T2 - Lessons from COMET-2

AU - Østergren, Peter B

AU - Murtola, Teemu J

AU - Fode, Mikkel

PY - 2018/12/17

Y1 - 2018/12/17

U2 - 10.1016/j.eururo.2018.12.016

DO - 10.1016/j.eururo.2018.12.016

M3 - Journal article

C2 - 30573315

SN - 0302-2838

JO - European Urology

JF - European Urology

ER -